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Abstract
Background: Mesenchymal stem cells are promising candidates in regenerative cell therapy. Conventional culture methods
involve the use of animal substances, specifically fetal bovine serum as growth supplement. Since the use of animal-derived
products is undesirable for human applications, platelet lysates produced from human platelets are an attractive alternative.
This is especially true if platelet lysates from already approved transfusion units at blood banks can be utilized. The purpose
of this study was to produce human platelet lysates from expired, blood bank-approved platelet concentrates and evaluate
their use as growth supplement in the culture of mesenchymal stem cells.
Methodology/Principal Findings: In this study, bone marrow-derived mesenchymal stem cells were cultured with one of
three culture supplements; fetal bovine serum, lysates from freshly prepared human platelet concentrates, or lysates from
expired human platelet concentrates. The effects of these platelet-derived culture supplements on basic mesenchymal stem
cell characteristics were evaluated. All cultures maintained the typical mesenchymal stem cell surface marker expression,
trilineage differentiation potential, and the ability to suppress in vitro immune responses. However, mesenchymal stem cells
supplemented with platelet lysates proliferated faster than traditionally cultured cells and increased the expression of the
osteogenic marker gene RUNX-2; yet no difference between the use of fresh and expired platelet concentrates was
observed.
Conclusion/Significance: Our findings suggest that human platelet lysates produced from expired platelet concentrates
can be used as an alternative to fetal bovine serum for mesenchymal stem cell culture to the same extent as lysates from
fresh platelets.
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Introduction
Platelets are small anucleated structures of hematopoietic origin
that contribute to hemostasis and wound healing by secreting
growth factors and cytokines. They are produced by the
fragmentation of megakaryocytes and released into the blood-
stream, where they circulate for 7–10 days before being replaced
[1]. Keeping the physiological levels of platelets well balanced is
essential since quantitative and qualitative platelet disorders can be
severe and difficult to treat, affecting the patient’s ability to
respond to bleeding and form adequate platelet plugs [2]. Due to
their importance, platelet contribution to hemostasis and biology
has been thoroughly evaluated in numerous studies in the past
[3,4]. Increased understanding has shed light on their role in
different biological processes apart from hemostasis and has fueled
research focusing on therapeutic application by exploiting their
growth factor secretion for potential clinical treatments such as
wound healing [5]. Platelet-based biomaterials such as platelet gel,
platelet glue and platelet rich plasma have recently been used in
oral/maxillofacial surgery, treatment of chronic ulcers and
orthopedics to facilitate healing and enhance bone-grafting
following implantation [6,7]. The possibility to use platelets to
improve cell culture techniques has also been studied in the past
few years, as well as their potential role in the design of novel
cellular therapies. So far, the results have been promising [8–12].
Clinical application of cellular therapy and regenerative
strategies are approaching a turning point, demanding increased
focus on developing culture methods that are devoid of animal-
derived products [13–15]. Common culture methods for the
expansion of mesenchymal stem cells (MSC) involve the use of
fetal bovine serum (FBS) to promote proliferation and survival.
This poses an undesirable risk for patients in the clinical setting, as
animal-derived products may cause immune-reactions towards
foreign factors as well as cross-species pathogen infections [14,16].
In the quest for replacing traditionally used FBS as growth
supplement in cell culture media, recent research has focused on
the application of platelet-derived products, e.g., platelet lysates
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that can be produced from regular platelet transfusion units by
lysis [8,11,17]. Based on these studies, platelet-derived products
have been suggested as viable alternative for the ex vivo culture of
cells for human therapy [9,12,18].
Although human platelet lysates (HPL) are emerging as a
possible option in the replacement of FBS in MSC cell culture,
caution is advised when handling products of human origin in
order to avoid transmission of infectious diseases. Therefore, it is
preferable that HPL applied in the clinical setting be manufac-
tured according to the same strict regulations as practiced in the
blood processing departments of blood banks and the general
hospital environment [10]. Another consideration involves the use
of human donors required for the production of HPL and platelet-
rich plasma. To date, there is already a shortage of blood and
platelet donors and it is thus undesirable to compete with blood
banks and transfusion centers for much needed freshly donated
platelets [19]. Platelet units have a relatively short shelf life and as
a result many donors are needed to maintain the minimum
number of platelet units available for transfusion at any given time.
Demand for platelets varies, making it difficult for blood banks to
estimate how many units are required. It has been reported that
up to 20% of all platelet units expire before they can be used and
are hence discarded [20]. The shelf life of platelet units is kept
short mostly because of increased risk of pathogen contamination
after few days of storage at room temperature and is not related to
platelet functionality [21]. After the short period of 5–7 days, units
are no longer considered safe for human transfusion even though
adequate platelet function may still be intact [22]. Hence, it might
be possible to use platelets for other purposes than transfusion after
they expire. Furthermore, the expired platelet units would have
been manufactured according to the accepted standards that apply
to the production of transfusion materials for human patients [23].
Human treatment involving the use of MSC is likely to be
applied in the clinical setting in the near future [24,25]. Numerous
clinical trials have demonstrated the safe use of MSC and the
possibility of taking advantage of their trilineage differentiation
potential to aid in the regeneration of mesenchymal tissues. Special
emphasis has been directed towards the use of MSC in the
treatment of bone and cartilage diseases, e.g., osteogenesis
imperfecta, osteoarthritis, and osteoporosis [24–31]. Furthermore,
therapeutic approaches for the treatment of autoimmune diseases
and the reduction of graft-versus-host responses have been
investigated based on the ability of MSC to modulate immune
responses [32–34].
Culture and maintenance of MSC in vitro is simple and cells can
be isolated from a variety of tissues [35,36]. Due to the innate
ability of these cells to adhere to plastic surfaces and proliferate
extensively in vitro, intense interest in the use of these cells in the
clinical setting has arisen [9,37,38]. It has been shown that the
expansion of MSC in growth media containing HPL produced
from freshly isolated platelet units instead of the traditionally used
FBS is feasible [9,11,18]. Therefore, the aim of this study was to
demonstrate for the first time that HPL derived from expired
platelet units can be used as alternative to FBS similarly to HPL
produced from freshly isolated platelet units. The use of expired
and fresh HPL did not affect any of the generally accepted basic
characteristics of MSC, i.e., cell surface antigen expression,
trilineage differentiation potential, and immunomodulatory func-
tions. However, an increase in the proliferation potential and the
expression of the osteogenic marker gene RUNX-2 was observed
in HPL supplemented cultures.
Results
HPL does not Affect Expression of MSC Surface Markers
Expression of selected surface markers: CD29, CD45, CD73,
CD90, CD105 and HLA-DR, was evaluated using flow-cytome-
try. MSC were cultured in media supplemented with one of three
different media supplements; FBS, HPL from fresh platelet
concentrates (HPLF), and HPL derived from expired platelet
concentrates (HPLO) for the total of three passages prior to
analysis. MSC from all cultures expressed CD29, CD73, CD90
and CD105 on their surface but not CD45 and HLA-DR
(Table 1). No difference in the expression of surface markers
dependent on culture conditions was observed.
HPL-supplemented Media Increases Proliferation of MSC
Cellular proliferation was evaluated by population doubling
assay over six passages of culture in media containing 10% of FBS,
HPLF or HPLO. Cultures supplemented with HPLF or HPLO
consistently proliferated faster than FBS supplemented cultures
(Figure 1). At the end of expansion over six passages, the
accumulated number of total population doublings (CPD) had
reached 13.7760.77 CPD for HPLO, 12.7760.12 CPD for HPLF
and 9.5061.14 CPD for FBS supplemented cultures, respectively.
This difference was most obvious after four to five passages with a
mean difference in CPD of 4.23360.7313 (p#0.05 ). These
findings were further supported by the calculation of generation
time. The average generation time between population doublings
was consistently shorter in HPLF and HPLO supplemented
cultures (2.2760.20 days for HPLO, 2.7160.37 days for HPLF
and 3.4160.13 days for FBS, respectively; p#0.05). However,
there was no significant difference in population doublings and
generation time between the use of HPLF and HPLO.
HPL Induced Morphological Changes during MSC
Expansion
Cell morphology was regularly evaluated during MSC culture
and repeated observations revealed morphology that was depen-
dent on the cell culture supplement. All cultures exhibited the
classical fibroblast-like morphology typical of MSC, yet cells grown
in HPL supplemented media were even more spindle shaped,
elongated, and showed denser cell-bodies than MSC from FBS
supplemented cultures (Figure 2A–C). In addition, a difference in
growth behavior could be observed. MSC cultured in HPL grew
in a manner that left circular areas free of cells, unlike FBS
supplemented cultures.
Table 1. Surface antigen expression of MSC cultured with
10% FBS, 10% HPLF or 10% HPLO.
FBS HPLF HPLO
CD 105 + + +
CD 29 + + +
CD 45 2 2 2
CD 73 + + +
CD 90 + + +
HLA-DR 2 2 2
doi:10.1371/journal.pone.0068984.t001
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Trilineage Differentiation Potential Remained Unaffected
by HPL
MSC in either of the three culture conditions could be
successfully differentiated towards adipocytes, chondrocytes, and
osteoblasts (Figure 2). After 28 days of osteogenic differentiation,
mineralization was observed in all cultures, as seen by the
precipitation of von Kossa stain (Figure 2D–F). Slightly more
mineralization could be observed in osteogenic cultures originating
from HPLF or HPLO treated MSC as compared to FBS treated.
Cultures supplemented with adipogenic stimulus underwent
morphological changes from a fibroblast-like appearance to round
cells with distinct lipid vacuoles in the cytoplasm, which stained
positive with Oil red O stain (Figure 2G–I). Chondrogenic cell-
pellets from all cultures had a chondrocytic appearance with
proliferating chondrocytes closer to the core of the pellet while
elongated cells were observed closer to the surface, forming a
sheath around the pellet in combination with extracellular matrix
(figure 2J–L).
MSCs Grown in HPL Suppress Mononuclear Cell
Proliferation
The immunomodulatory functions of MSC were evaluated by
mixed lymphocyte reaction assays after cell expansion in any of the
three culture supplemented media. The proliferation of stimulated
mononuclear cells (MNC) co-cultured with MSC was compared to
MNC proliferation in the absence of MSC. Co-culture of MSC
with MNC significantly reduced the proliferation of MNC as
compared to MNC alone (p#0.05, Figure 3). The use of HPL or
FBS as culture supplements during cell expansion did not affect
the ability of MSC to reduce MNC proliferation.
Alkaline Phosphatase (ALP) Activity is Temporarily
Decreased in HPLF Supplemented Cultures
Enzymatic activity of ALP increased during osteogenic differ-
entiation in all MSC, independent of the supplement used. After 7
days of osteogenic differentiation, ALP activity was significantly
lower in cultures supplemented with HPLF compared to FBS
(1.7360.27 nMol(p-nitrophenol)/min/mg protein for HPLF and
2.7660.01 nMol(p-nitrophenol)/min/mg protein for FBS,
p#0.05), yet no effect could be ascribed to the use of HPLO
(Figure 4). This decrease in ALP activity disappeared after 14 days
in culture, removing any differences in ALP activity that could be
attributed to the use of either supplement. Overall, ALP activity
increased significantly from 7 to 14 days in the presence of
osteogenic stimulus ranging from 1.4 fold increase for FBS and
1.86 fold increase for HPLO to 2.6 fold increase for HPLF
(p#0.05).
Expression Pattern of Osteogenic Marker Genes
Before and during osteogenic differentiation, the expression of
the three following osteogenic marker genes was analyzed, i.e.,
Runt –related transcription factor 2 (RUNX2), Secreted phospho-
protein 1 (SPP1), and Alkaline phosphatase (ALP). The choice of
these specific marker genes comprehensively represents the
different stages of osteogenic differentiation, with RUNX-2 as
early marker, SPP1 as late marker, and ALP as steadily expressed
marker gene.
The expansion of MSC in FBS and HPL supplemented media
did not affect the expression of osteogenic marker genes before the
initiation of differentiation and thus the cells were not primed
toward the osteogenic lineage during expansion. Through the
course of osteogenic differentiation, RUNX-2 expression decreased
over a time period of 21 days (p#0.01), whereas SPP1 expression
significantly increased (p#0.01), as expected (Figure 5). Differenc-
es in ALP expression could be attributed to donor variation
(p#0.05), yet no effect of the culture supplements was observed.
During early time points (7 days), HPLO significantly increased
the expression of RUNX-2 (p#0.05) as compared to HPLF and
FBS supplemented cultures, which was still true after 21 days in
culture (p#0.01). No difference in RUNX-2 expression was
observed after 7 days between HPLF and FBS use, yet after 21
days in the presence of an osteogenic stimulus, HPLF, similar to
HPLO, significantly increased RUNX-2 expression as compared to
FBS supplemented cultures (p#0.01). The expression of SPP1 and
ALP was similar at individual time-points in any of the cultures
evaluated.
Discussion
In this study, the use of HPL prepared from expired platelet
concentrates (HPLO) as growth supplement for MSC culture was
compared to HPL derived from fresh platelet concentrates (HPLF)
and the traditional use of FBS. Basic MSC characteristics, i.e.,
surface antigen expression, trilineage differentiation potential and
immune-suppression, remained unaltered. However, the use of
HPL as MSC growth supplement induced morphological changes,
significantly increased proliferation, and resulted in elevated levels
of RUNX-2 during osteogenic differentiation.
All cultures displayed the typical MSC morphology, with long,
fibroblast-like cell bodies during expansion. HPL supplementation
of the growth media resulted in morphological changes, allowing
growth in higher numbers per unit area. The spherical growth
pattern of HPL supplemented cultures was accompanied by
circular areas free of cell growth before cultures reached
confluence. Similar morphological changes have been shown in
Figure 1. Cumulative population doublings of MSC after
culture in FBS, HPLF or HPLO. MSC were cultured in culture media
supplemented with 10% of FBS, platelet lysate from fresh platelet
concentrates (HPLF) or lysate from expired platelet concentrates
(HPLO). Population doubling assay was performed at the end of every
passage for a total of six passages (P1–P6, n = 3). MSC cultured in either
HPLF or HPLO consistently had higher numbers of population
doublings at the end of every passage compared to MSC cultured in
FBS. By the end of the sixth passage cumulative population doublings
were 13.7760.77 CPD for HPLO, 12.7760.12 CPD for HPLF and
9.5061.14 CPD for FBS supplemented cultures, respectively.
doi:10.1371/journal.pone.0068984.g001
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Figure 2. Mesenchymal stem cell morphology during expansion and differentiation. MSC were stained with crystal violet after expansion
in media containing 10% of FBS, HPLF or HPLO for three passages (A–C). MSC cultured in HPLF or HPLO developed more spindle shaped morphology
than cells cultured in FBS, proliferated faster and left circular areas containing no cells between them. Differentiation towards osteoblasts, adipocytes
Platelet Lysate Support Expansion of Stem Cells
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other studies using HPL supplemented media for MSC expansion.
This change in morphology could be due to the presence of
additional factors in HPL, which are not generally found in FBS,
e.g., serotonin.
Serotonin is stored in platelets and is known to affect cellular
morphology of neural cells and cause vasoconstriction of
endothelial cells [39]. Since there are indications that MSC reside
as pericytes within the vasculature, serotonin levels could affect
cellular morphology, resulting in cell contraction. Whether the
morphological changes alter MSC biological functions remains
speculative but there are some indications that serotonin also plays
a role in bone-tissue regulation and hence effects on MSCs might
be worthy to explore [40,41].
Proliferation in the presence of HPL as growth supplement was
continuously faster than traditionally cultured MSC. This trend
has been described before and also encompasses other growth
supplements derived from platelet units. Since the use of expired
or fresh HPL did not affect the increased rate of expansion, the
utilization of expired platelet units as growth supplements for
MSC expansion may be advantageous. This increase in prolifer-
ation and the rate of population doublings could be due to certain
growth factors present in HPL. However, since the number of
MSC population doublings in vitro is limited to 25–50, fast cellular
proliferation in HPL may cause the cells to cease expansion at
earlier passages than seen in FBS supplemented cultures.
Therefore it is interesting that Horn et al. showed that MSC
grown in the presence of HPL may reach higher population
doublings than cells grown in FBS [42,43].
In addition, HPL supplemented media could be used to the
same extent as FBS containing media for the neutralization of
trypsin during passaging of cells. This indicates that platelet lysates
might have similar protective abilities generally attributed to FBS,
yet without providing proteolytic inhibitors.
MSC immunomodulatory functions were maintained indepen-
dent of the growth supplement used for cell expansion. The MNC
population used in this study is comprised of several distinct cell
populations, i.e., lymphocytes, natural killer cells, and monocytes.
The lymphocyte population can be further divided into subpop-
ulations, including T-Cells (regulatory T-cells, T-helper 1 cells,
and T-helper 2 cells) as well as B-cells. The immunomodulatory
abilities of MSC are strongly dependent on the immune cell
population, resulting in increased proliferation of T-regulatory
cells and T-helper 2 cells, whereas proliferation of T-cells, B-cells,
and natural killer cells is suppressed [44,45]. The focus of the
present study was on the general effect of immunomodulatory
functions rather than the individual effect of MSC on each of the
immune-cell populations.
In the course of osteogenic differentiation, MSC underwent the
typical morphological changes from fibroblast-like cells to cells
with cuboidal shape, capable of mineralization. Enzymatic activity
of ALP significantly increased between 7 and 14 days of osteogenic
differentiation, indicating successful transition to osteoblasts. At
early time points (7 days), HPLF supplemented cultures showed
significantly less ALP activity as compared to HPLO and FBS
growth supplements. However, since the activity of ALP was not
significantly different at 14 days, the overall effect on the quality of
osteogenic differentiation is expected to be minimal. Interestingly,
ALP activity was consistently similar in HPLO, yet not HPLF, and
FBS supplemented cultures.
In order to exclude the possibility of lineage-specific cell priming
by use of HPL as growth supplement, the expression of osteogenic
marker genes was evaluated after expansion for 7 days in the
absence of an osteogenic stimulus.
No induction of osteogenic marker gene expression was
observed in any of the samples prior to osteogenic differentiation;
indicating that MSC expansion in HPL does not induce priming
towards osteogenesis and thusly expanded cells may be used for
differentiation towards any of the established mesenchymal
lineages. In addition, osteogenic differentiation was verified by
the expression of well-known osteogenic marker genes, i.e., RUNX-
2, ALP, and SPP1. Expression of SPP1 increased during the course
of 21 days as expected, however, a continuous and steady
expression of ALP was observed even though the activity of the
enzymatic product was seen to increase throughout the differen-
tiation process. This might point towards posttranslational
regulation of ALP. The expression of the two marker genes,
SPP1 and ALP, was not affected by the growth media supplements
used in this study. However, the expression of the early marker
RUNX-2 was significantly higher in HPL supplemented cultures.
This was especially pronounced for HPLO as growth supplements,
which increased expression even at early time points, followed by
HPLF at 21 days of culture.
Expression of RUNX2 plays a central role in committing MSCs
towards the osteoprogenitor lineage and subsequently upregulates
expression of other factors necessary for osteogenesis such as Wnts
[46]. High RUNX2 expression is indicative of good quality
osteogenic differentiation and limits the differentiation towards
other lineages. The effect on RUNX2 gene expression is not
entirely surprising, since platelet lysates can contain factors that
and chondrocytes was initiated after expansion in the three supplements. After 28 days of osteogenic differentiation mineralization in the culture
could be visualized with a Von Kossa staining (D–F). Successful adipogenic differentiation was confirmed with Oil red O staining (G–I) and after 28
days of chondrogenic pellet cultures, the pellets were sectioned and stained with toludine blue staining (J–L). Pictures representative of three
experiments.
doi:10.1371/journal.pone.0068984.g002
Figure 3. Reduction of mononuclear cell proliferation during
co-culture with MSC. Mononuclear cells (MNC) were stimulated with
phytohemaglutinin (PHA) and then cultured with or without MSC that
had been previously expanded in media containing 10% of FBS, HPLF or
HPLO. MNC proliferation was significantly less when co-cultured with
MSC than if cultured on their own (p#0.05, n = 3). The reduced
proliferation was seen irrespective of the culture conditions the MSC
had previously been exposed to. * = p#0.05.
doi:10.1371/journal.pone.0068984.g003
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participate in osteogenesis and normal bone turn-over, such as
calcitonin and ostecalcin. Therefore, HPL may be able to enhance
expression of osteogenic marker genes after initiation of osteogen-
esis. In turn, this may lead to faster and better quality
differentiation, yet does not prime cells towards the osteogenic
lineage, as discussed above. These findings are in agreement with
previous publications and overall indicate successful osteogenic
differentiation in all samples.
Consequently, the use of HPL supplemented media may be
advantageous for faster MSC expansion and improved differen-
tiation as compared to the traditional use of FBS. Since no
difference between expired and fresh HPL could be observed,
expired platelet units at blood banks and transfusion centers are an
attractive option for MSC culture, instead of being discarded as is
the general practice today.
Conclusion
In the present study, the effect of platelet lysates prepared from
expired (HPLO) and fresh platelet (HPLF) units was compared to
the traditional use of FBS in the culture of mesenchymal stem cells
(MSC). By using HPLO as MSC growth supplement, high quality
osteogenic differentiation as well as increased proliferation rates
can be achieved without affecting basic cell characteristics, i.e.,
surface antigen expression, trilineage differentiation potential, and
immune-suppression. Consequently, expired platelet transfusion
units, currently a waste product in blood processing departments,
represent a potential substitute for the use of animal-derived FBS,
decreasing the risk of pathogen contamination and immune
reactions to xenogenic proteins. Furthermore, the use of expired
platelet units is free of ethical concerns and does not compete with
the requirements of patients for platelet transfusions. Therefore,
HPL derived from expired platelet units constitutes a feasible and
cost-effective replacement for the use of FBS in MSC culture.
Materials and Methods
Preparation of Platelet Lysates
Transfusion units of platelet rich concentrates, derived from
buffy coats, were obtained from the processing department at the
Blood Bank, Landspitali University Hospital, Reykjavik, Iceland.
Half of the units were stored immediately at 280uC (fresh units;
HPLF), whereas the other half was stored for six days at room
temperature in a shaking incubator until expired, and then placed
in 280uC storage (expired/outdated units; HPLO). Before
processing, frozen units were thawed in a 37uC water bath,
resulting in platelet lysis. After 20 min centrifugation at 4975 g,
supernatants were collected and filtered through a 40 mm cell
strainer (BD Falcon, Franklin lakes, NJ, USA) and the pellet was
subsequently discarded. Then, the filtrate was transferred to
0.45 mm Stericups (Millipore, Billerica, MA, USA) and filtered
under 20.9 bar pressure, resulting in a pool of filtered lysate,
which was subsequently centrifuged for 20 min at 4975 g and
filtered again through a cell strainer. Aliquots were stored at
280uC. Before use as a growth supplement in cell culture media,
aliquots were centrifuged at 4975 g for 10 min and only
supernatants were used.
Cell Culture
Human, bone marrow-derived MSC, negative for HIV-I,
hepatitis B- and C viruses, from three donors were obtained from
Lonza, Walkersville, MD, USA. After initial expansion in
Standard Mesenchymal Stem Cell Basal medium (Lonza) cells
were split into three separate cultures for further expansion in
DMEM/F12 media (Gibco, Grand Island, NY, USA) containing
1% penicillin/streptomycin (Gibco), 4 IU/ml heparin (LEO
Pharma A/S, Ballerup, Denmark), and supplemented with either
10% HPLF, 10% HPLO, or 10% MSC- approved FBS (Gibco),
Figure 4. Increased enzymatic activity of alkaline phosphatase during osteogenic differentiation. MSC that had previously been
cultured in media containing 10% of FBS, HPLF or HPLO underwent osteogenic differentiation. ALP activity was evaluated after 7 and 14 days of
differentiation. ALP activity increased significantly from day 7 to day 14 independent of the type of culture conditions the MSC had been exposed to
prior to osteogenic differentiation (p#0.05, n = 3). * = p#0.05.
doi:10.1371/journal.pone.0068984.g004
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respectively. Cells were cultured in an incubator at 5% CO2, 95%
humidity, and 37uC. Cells from each of the three donors were
cultured independently and experiments performed in triplicates.
Population Doubling Assay
Proliferation rate was analyzed by determining population
doublings (PD) at the end of each passage for six passages using the
following formula [11]:
PD~
log10(NH ){log10(N1)
log10(2)
where NH denotes the number of cells retrieved at the end of the
passage and N1 denotes the number of cells seeded at the
beginning of the passage. For the calculation of cumulative PD,
the number of PD at the end of each passage was added to the PD
of previous passages.
Phenotype Confirmation
Surface antigen expression was analyzed in a FACSCalibur
Flow Cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) for
105 cells/antibody. Antibodies were purchased from Becton
Dickinson and included CD29, CD45, CD73, CD90, CD105
and HLA-DR. Cell suspensions were incubated for 20 minutes
with 10 ml antibodies, diluted with PBS and vortexed prior to
analysis. Data was analysed using CellQuestPro Software 4.0.2.
Figure 5. Expression of osteogenic marker genes during osteogenic differentiation of MSC. Osteogenic differentiation was initiated after
MSC expansion in 10% of FBS, HPLF or HPLO. Expression of osteogenic marker genes was evaluated after 7 and 21 days of osteogenic differentiation
and is represented with graphs for each gene (A–C, n = 3) and a heat-map (D) where green shades represent lower levels of expression and red
shades higher levels of expression. ALP was evenly expressed throughout the differentiation (A,D) while the expression of SPP1 increased from day 7
to day 21 (B,D), irrespective of the culture supplements the MSC had previously been exposed to (p#0.01). Expression of RUNX2 decreased from day
7 to day 21 for all cultures (C–D), still expression of RUNX2 in cultures originating from HPLO treated MSC was higher at both time-points compared to
FBS and also at day 21 for HPLF compared to FBS (p#0.05). * = p#0.05, ** = p#0.01.
doi:10.1371/journal.pone.0068984.g005
Platelet Lysate Support Expansion of Stem Cells
PLOS ONE | www.plosone.org 7 July 2013 | Volume 8 | Issue 7 | e68984
Immunomodulation
The ability of MSC to suppress proliferation of mononuclear
cells (MNC) stimulated with phytohemagglutinin (PHA) was
analyzed using a mixed lymphocyte reaction assay (MLR). MSCs
were seeded at a density of 25.000 MSC/cm2 in 24-well plates
with RPMI 1640 media (Lonza) containing 10% MSC-FBS and
allowed to adhere overnight in an incubator. The following day,
media was fully replaced and semi-permeable inserts with 8 mm
pores (BD Falcon) were placed in the wells and used to prevent
direct contact of MSC and MNC. MNC were isolated from buffy
coats of donor blood using the ficoll method [47] and seeded in
RPMI 1640 medium with 10% MSC-FBS into the inserts
(500.000 MNC/insert). MNC proliferation was stimulated with
1.5 mg/ml PHA (Sigma, St. Louis, MO, USA). Control wells
included unstimulated MNC and stimulated MNC in the absence
of MSC. MNC proliferation was analyzed after 48 h with an XTT
assay following manufacturer’s instructions (ATCC, Munassas,
VA, USA). Optical density was measured in a MultiSkan
spectrometer (Thermo Scientific, Vantaa, Finland) at 475 nm.
Measurements at 660 nm were used to reduce the signal-to-noise
ratio.
In vitro Differentiation
After three passages of expansion in either of the supplemented
media, differentiation towards adipogenic, chondrogenic and
osteogenic lineages was initiated in commercially prepared
differentiation media for each lineage (Lonza, Gibco).
For osteogenic differentiation, cells were seeded in monolayers
at a density of 3000 cells/cm2 in Mesenchymal Stem Cell
Osteogenic Differentiation Media (Lonza). Mineralization was
visualized with Alizarin Red Staining. Activity of alkaline
phosphatase (ALP) in osteogenic cells was determined after 7
and 14 days by the conversion of p-Nitrophenolphosphate to p-
Nitrophenyl (Sigma, St. Louis, MO, USA). For gene expression
studies, samples were taken after 7 and 21 days of osteogenic
differentiation.
Chondrocytic differentiation was performed in pellet cultures
using complete Mesenchymal Stem Cell Chondrocyte Differenti-
ation Medium (Lonza) with an initial seeding density of 250.000
cells/pellet and cultured for 28 days. For staining with toluidine
blue, pellets were collected and sectioned following standard
procedures.
For adipocytic differentiation, 10.000 cells/cm2 were seeded in
monolayers with StemProH Adipogenesis Differentiation medium
(Gibco) and maintained for 14 days. Adipocytic cultures were
stained with Oil red O staining for visualization of lipid vacuoles.
Images were taken in an inverted microscope using Infinity
Capture 2.0 Software (Lumenerea, Capella court, Ottawa, ON,
Canada).
Gene Expression Analysis
Real-Time qPCR for the osteogenic marker genes runt-related
transcription factor 2 (RUNX2), ALP and secreted phosphoprotein
1 (SPP1) was performed on samples obtained before iniation of
differentiation and after 7 and 21 days in culture. RNA extraction,
cDNA synthesis and Real-Time PCR was performed by TATAA
Biocenter, Sweden.
Briefly, RNA was isolated using the RNeasyH Mini Kit (Qiagen,
Hamburg, Germany) in a Qiagen BioRobot Workstation (Qia-
gen). During extraction, gDNA contamination was reduced by
treating samples with RNase free DNase Set (Qiagen). Extracted
RNA was analyzed for RNA quantity and quality with a
NanoDrop ND-1000 spectrophotometer (Thermo Scientific). All
steps were performed according to manufacturer‘s instructions.
Reverse transcription was performed with TATAA Grand-
ScripTTM kit (TATAA Biocenter AB, Gothenburg, Sweden) in
single 20 ml reactions. Reverse transcription controls were
included to monitor the presence of gDNA.
RT-qPCR analysis was performed on all samples with RUNX2,
ALP and SPP1 as genes of interest. All qPCR assays were
performed in duplicate in a 10 ml reaction volume using the
LightCycler 480 instrument (Roche Applied Science Inc.,
Indianapolis, IN, USA) with TATAA SYBRH GrandMasterTM
Mix (TATAA Biocenter AB). Samples were amplified for 45 cycles
and analyzed with the TATAA Human Reference Gene panel.
Primers for genes of interest were designed by TATAA Biocenter
AB. All experiments were performed according to manufacturer’s
instructions.
Statistical Analysis
GraphPadH version 5.0 software was used for all analysis except
for analysis of gene expression. GenEx 5.2.3.13 software was used
to analyze gene expression. Two-way ANOVA was used where
applicable and Student’s t-test was used to confirm statistical
significance. P,0.05 was considered statistically significant.
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